Loading…
Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
The effect and safety of Semaglutide and Liraglutide on weight loss in people with obesity or overweight were evaluated by a Network Meta-Analysis system to provide an evidence-based reference for clinical treatment. Computer searched PubMed, Embase, and Cochrane Library databases to collect Liraglu...
Saved in:
| Published in: | Clinical epidemiology 2022-01, Vol.14, p.1463-1476 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c619t-f73176c4384a9bde746e9ad24ec68437cd9431447ffd8d83e1e713fae428a68e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c619t-f73176c4384a9bde746e9ad24ec68437cd9431447ffd8d83e1e713fae428a68e3 |
| container_end_page | 1476 |
| container_issue | |
| container_start_page | 1463 |
| container_title | Clinical epidemiology |
| container_volume | 14 |
| creator | Xie, Zeyu Yang, Sensen Deng, Weishang Li, Jinjian Chen, Jisheng |
| description | The effect and safety of Semaglutide and Liraglutide on weight loss in people with obesity or overweight were evaluated by a Network Meta-Analysis system to provide an evidence-based reference for clinical treatment.
Computer searched PubMed, Embase, and Cochrane Library databases to collect Liraglutide and Semaglutide injection monotherapy RCTs until April 2022, using Stata 16 software for Network Meta-Analysis.
Twenty-three RCTs study with 11,545 patients and 4 interventions (semaglutide 2.4mg, semaglutide 1.0mg, liraglutide 3.0mg and liraglutide 1.8 mg) were finally included. In terms of efficacy, semaglutide 2.4mg (-12.47 kg) had the best weight loss, followed by liraglutide 3.0mg (-5.24 kg), semaglutide 1.0mg (-3.74 kg) and liraglutide 1.8mg (-3.29 kg). In terms of decreased HbA1c, semaglutide 2.4mg (MD=-1.48%, 95% CI [-1.93, -1.04]), semaglutide 1.0mg (MD=-1.36%, 95% CI [-1.72, -1.01]), liraglutide 1.8mg (MD=-1.23%, 95%Cl [-1.66, -0.80]) more effective than placebo. In terms of safety, the total incidence of adverse events was semaglutide 2.4mg > liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 1.0mg compare to placebo, the incidence of serious adverse events was liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 2.4mg > semaglutide 1.0mg, the incidence of hypoglycemic events was semaglutide 2.4mg > liraglutide 3.0mg > semaglutide 1.0mg > liraglutide 1.8mg.
This meta-analysis indicates that all GLP-1RAs were more efficacious than placebo in people with obesity or overweight on efficacy. Semaglutide 2.4mg has an absolute advantage in weight loss and decreased HbA1c, but the incidence of total adverse events is also the highest and can cause hypoglycemia. In addition, although liraglutide 3.0mg was less effective than semaglutide 2.4mg, serious adverse events were still the most elevated. |
| doi_str_mv | 10.2147/CLEP.S391819 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_24d9f5c996444915b47900676c50fa9c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A733406516</galeid><doaj_id>oai_doaj_org_article_24d9f5c996444915b47900676c50fa9c</doaj_id><sourcerecordid>A733406516</sourcerecordid><originalsourceid>FETCH-LOGICAL-c619t-f73176c4384a9bde746e9ad24ec68437cd9431447ffd8d83e1e713fae428a68e3</originalsourceid><addsrcrecordid>eNptktGP0yAcxxuj8S7nvflsSEyMD26WQgv4YLIsu_OSJbs4jY-EwY-NpSsTui2L_7z0NudmLA9t4cMH-PHNstc47xeYso_D8eixPyUCcyyeZdcYM9HDhIrnZ99X2W2Myzw9hGDG8pfZFalKnFPOr7NfI2udVnqPVGPQVFlo98hbNHZBzetN6wwcRmB1-vcN-gFuvmjR2MeIXIMewa9rQDvXLtBkBtF1koAmWwi7J_ITGqDpPrbJ0jqNvsLWwe5V9sKqOsLt8X2Tfb8bfRt-6Y0n9w_DwbinKyzanmVp25WmhFMlZgYYrUAoU1DQFaeEaSMowZQyaw03nAAGholVQAuuKg7kJns4eI1XS7kObqXCXnrl5FOHD3OpQtpWDbKgRthSC1FRSgUuZ5SJPK_S8mVuldDJ9fngWm9mKzAamjao-kJ6OdK4hZz7rRSMcFzxJHh_FAT_cwOxlSsXNdS1asBvoixYSdPVFKRI6Nt_0KXfhCaVqqNKLMqiyP9Sc5UO4Brr07q6k8oBI4Tm6a6rRPX_Q6VmYOW0b8C61H8x4d3ZhAWoul1E3yXAN_ES_HAAdUhpCGBPxcC57EIqu5DKY0gT_ua8gCf4TyTJb50X3zg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2755195220</pqid></control><display><type>article</type><title>Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review</title><source>Taylor & Francis</source><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Xie, Zeyu ; Yang, Sensen ; Deng, Weishang ; Li, Jinjian ; Chen, Jisheng</creator><creatorcontrib>Xie, Zeyu ; Yang, Sensen ; Deng, Weishang ; Li, Jinjian ; Chen, Jisheng</creatorcontrib><description>The effect and safety of Semaglutide and Liraglutide on weight loss in people with obesity or overweight were evaluated by a Network Meta-Analysis system to provide an evidence-based reference for clinical treatment.
Computer searched PubMed, Embase, and Cochrane Library databases to collect Liraglutide and Semaglutide injection monotherapy RCTs until April 2022, using Stata 16 software for Network Meta-Analysis.
Twenty-three RCTs study with 11,545 patients and 4 interventions (semaglutide 2.4mg, semaglutide 1.0mg, liraglutide 3.0mg and liraglutide 1.8 mg) were finally included. In terms of efficacy, semaglutide 2.4mg (-12.47 kg) had the best weight loss, followed by liraglutide 3.0mg (-5.24 kg), semaglutide 1.0mg (-3.74 kg) and liraglutide 1.8mg (-3.29 kg). In terms of decreased HbA1c, semaglutide 2.4mg (MD=-1.48%, 95% CI [-1.93, -1.04]), semaglutide 1.0mg (MD=-1.36%, 95% CI [-1.72, -1.01]), liraglutide 1.8mg (MD=-1.23%, 95%Cl [-1.66, -0.80]) more effective than placebo. In terms of safety, the total incidence of adverse events was semaglutide 2.4mg > liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 1.0mg compare to placebo, the incidence of serious adverse events was liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 2.4mg > semaglutide 1.0mg, the incidence of hypoglycemic events was semaglutide 2.4mg > liraglutide 3.0mg > semaglutide 1.0mg > liraglutide 1.8mg.
This meta-analysis indicates that all GLP-1RAs were more efficacious than placebo in people with obesity or overweight on efficacy. Semaglutide 2.4mg has an absolute advantage in weight loss and decreased HbA1c, but the incidence of total adverse events is also the highest and can cause hypoglycemia. In addition, although liraglutide 3.0mg was less effective than semaglutide 2.4mg, serious adverse events were still the most elevated.</description><identifier>ISSN: 1179-1349</identifier><identifier>EISSN: 1179-1349</identifier><identifier>DOI: 10.2147/CLEP.S391819</identifier><identifier>PMID: 36510488</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Analysis ; Bias ; Body mass index ; Clinical medicine ; Complications and side effects ; Coronaviruses ; COVID-19 ; Database searching ; Diabetes ; Drug dosages ; Epidemiology ; Evidence-based medicine ; Glucagon ; glucagon-like peptide-1 receptor agonists ; Hypoglycemia ; Internet/Web search services ; Intervention ; Liraglutide ; Medical research ; Medicine, Experimental ; Obesity ; Online searching ; Overweight ; Peptides ; Review ; semaglutide ; Sitagliptin ; Software reviews ; Systematic review ; Type 2 diabetes ; Weight control ; Weight loss</subject><ispartof>Clinical epidemiology, 2022-01, Vol.14, p.1463-1476</ispartof><rights>2022 Xie et al.</rights><rights>COPYRIGHT 2022 Dove Medical Press Limited</rights><rights>2022. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Xie et al. 2022 Xie et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c619t-f73176c4384a9bde746e9ad24ec68437cd9431447ffd8d83e1e713fae428a68e3</citedby><cites>FETCH-LOGICAL-c619t-f73176c4384a9bde746e9ad24ec68437cd9431447ffd8d83e1e713fae428a68e3</cites><orcidid>0000-0002-8326-3214 ; 0000-0002-1609-4377 ; 0000-0003-1131-6417 ; 0000-0003-3514-9086</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2755195220/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2755195220?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36510488$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xie, Zeyu</creatorcontrib><creatorcontrib>Yang, Sensen</creatorcontrib><creatorcontrib>Deng, Weishang</creatorcontrib><creatorcontrib>Li, Jinjian</creatorcontrib><creatorcontrib>Chen, Jisheng</creatorcontrib><title>Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review</title><title>Clinical epidemiology</title><addtitle>Clin Epidemiol</addtitle><description>The effect and safety of Semaglutide and Liraglutide on weight loss in people with obesity or overweight were evaluated by a Network Meta-Analysis system to provide an evidence-based reference for clinical treatment.
Computer searched PubMed, Embase, and Cochrane Library databases to collect Liraglutide and Semaglutide injection monotherapy RCTs until April 2022, using Stata 16 software for Network Meta-Analysis.
Twenty-three RCTs study with 11,545 patients and 4 interventions (semaglutide 2.4mg, semaglutide 1.0mg, liraglutide 3.0mg and liraglutide 1.8 mg) were finally included. In terms of efficacy, semaglutide 2.4mg (-12.47 kg) had the best weight loss, followed by liraglutide 3.0mg (-5.24 kg), semaglutide 1.0mg (-3.74 kg) and liraglutide 1.8mg (-3.29 kg). In terms of decreased HbA1c, semaglutide 2.4mg (MD=-1.48%, 95% CI [-1.93, -1.04]), semaglutide 1.0mg (MD=-1.36%, 95% CI [-1.72, -1.01]), liraglutide 1.8mg (MD=-1.23%, 95%Cl [-1.66, -0.80]) more effective than placebo. In terms of safety, the total incidence of adverse events was semaglutide 2.4mg > liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 1.0mg compare to placebo, the incidence of serious adverse events was liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 2.4mg > semaglutide 1.0mg, the incidence of hypoglycemic events was semaglutide 2.4mg > liraglutide 3.0mg > semaglutide 1.0mg > liraglutide 1.8mg.
This meta-analysis indicates that all GLP-1RAs were more efficacious than placebo in people with obesity or overweight on efficacy. Semaglutide 2.4mg has an absolute advantage in weight loss and decreased HbA1c, but the incidence of total adverse events is also the highest and can cause hypoglycemia. In addition, although liraglutide 3.0mg was less effective than semaglutide 2.4mg, serious adverse events were still the most elevated.</description><subject>Analysis</subject><subject>Bias</subject><subject>Body mass index</subject><subject>Clinical medicine</subject><subject>Complications and side effects</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Database searching</subject><subject>Diabetes</subject><subject>Drug dosages</subject><subject>Epidemiology</subject><subject>Evidence-based medicine</subject><subject>Glucagon</subject><subject>glucagon-like peptide-1 receptor agonists</subject><subject>Hypoglycemia</subject><subject>Internet/Web search services</subject><subject>Intervention</subject><subject>Liraglutide</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Obesity</subject><subject>Online searching</subject><subject>Overweight</subject><subject>Peptides</subject><subject>Review</subject><subject>semaglutide</subject><subject>Sitagliptin</subject><subject>Software reviews</subject><subject>Systematic review</subject><subject>Type 2 diabetes</subject><subject>Weight control</subject><subject>Weight loss</subject><issn>1179-1349</issn><issn>1179-1349</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptktGP0yAcxxuj8S7nvflsSEyMD26WQgv4YLIsu_OSJbs4jY-EwY-NpSsTui2L_7z0NudmLA9t4cMH-PHNstc47xeYso_D8eixPyUCcyyeZdcYM9HDhIrnZ99X2W2Myzw9hGDG8pfZFalKnFPOr7NfI2udVnqPVGPQVFlo98hbNHZBzetN6wwcRmB1-vcN-gFuvmjR2MeIXIMewa9rQDvXLtBkBtF1koAmWwi7J_ITGqDpPrbJ0jqNvsLWwe5V9sKqOsLt8X2Tfb8bfRt-6Y0n9w_DwbinKyzanmVp25WmhFMlZgYYrUAoU1DQFaeEaSMowZQyaw03nAAGholVQAuuKg7kJns4eI1XS7kObqXCXnrl5FOHD3OpQtpWDbKgRthSC1FRSgUuZ5SJPK_S8mVuldDJ9fngWm9mKzAamjao-kJ6OdK4hZz7rRSMcFzxJHh_FAT_cwOxlSsXNdS1asBvoixYSdPVFKRI6Nt_0KXfhCaVqqNKLMqiyP9Sc5UO4Brr07q6k8oBI4Tm6a6rRPX_Q6VmYOW0b8C61H8x4d3ZhAWoul1E3yXAN_ES_HAAdUhpCGBPxcC57EIqu5DKY0gT_ua8gCf4TyTJb50X3zg</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Xie, Zeyu</creator><creator>Yang, Sensen</creator><creator>Deng, Weishang</creator><creator>Li, Jinjian</creator><creator>Chen, Jisheng</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8C1</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8326-3214</orcidid><orcidid>https://orcid.org/0000-0002-1609-4377</orcidid><orcidid>https://orcid.org/0000-0003-1131-6417</orcidid><orcidid>https://orcid.org/0000-0003-3514-9086</orcidid></search><sort><creationdate>20220101</creationdate><title>Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review</title><author>Xie, Zeyu ; Yang, Sensen ; Deng, Weishang ; Li, Jinjian ; Chen, Jisheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c619t-f73176c4384a9bde746e9ad24ec68437cd9431447ffd8d83e1e713fae428a68e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Bias</topic><topic>Body mass index</topic><topic>Clinical medicine</topic><topic>Complications and side effects</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Database searching</topic><topic>Diabetes</topic><topic>Drug dosages</topic><topic>Epidemiology</topic><topic>Evidence-based medicine</topic><topic>Glucagon</topic><topic>glucagon-like peptide-1 receptor agonists</topic><topic>Hypoglycemia</topic><topic>Internet/Web search services</topic><topic>Intervention</topic><topic>Liraglutide</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Obesity</topic><topic>Online searching</topic><topic>Overweight</topic><topic>Peptides</topic><topic>Review</topic><topic>semaglutide</topic><topic>Sitagliptin</topic><topic>Software reviews</topic><topic>Systematic review</topic><topic>Type 2 diabetes</topic><topic>Weight control</topic><topic>Weight loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xie, Zeyu</creatorcontrib><creatorcontrib>Yang, Sensen</creatorcontrib><creatorcontrib>Deng, Weishang</creatorcontrib><creatorcontrib>Li, Jinjian</creatorcontrib><creatorcontrib>Chen, Jisheng</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Clinical epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xie, Zeyu</au><au>Yang, Sensen</au><au>Deng, Weishang</au><au>Li, Jinjian</au><au>Chen, Jisheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review</atitle><jtitle>Clinical epidemiology</jtitle><addtitle>Clin Epidemiol</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>14</volume><spage>1463</spage><epage>1476</epage><pages>1463-1476</pages><issn>1179-1349</issn><eissn>1179-1349</eissn><abstract>The effect and safety of Semaglutide and Liraglutide on weight loss in people with obesity or overweight were evaluated by a Network Meta-Analysis system to provide an evidence-based reference for clinical treatment.
Computer searched PubMed, Embase, and Cochrane Library databases to collect Liraglutide and Semaglutide injection monotherapy RCTs until April 2022, using Stata 16 software for Network Meta-Analysis.
Twenty-three RCTs study with 11,545 patients and 4 interventions (semaglutide 2.4mg, semaglutide 1.0mg, liraglutide 3.0mg and liraglutide 1.8 mg) were finally included. In terms of efficacy, semaglutide 2.4mg (-12.47 kg) had the best weight loss, followed by liraglutide 3.0mg (-5.24 kg), semaglutide 1.0mg (-3.74 kg) and liraglutide 1.8mg (-3.29 kg). In terms of decreased HbA1c, semaglutide 2.4mg (MD=-1.48%, 95% CI [-1.93, -1.04]), semaglutide 1.0mg (MD=-1.36%, 95% CI [-1.72, -1.01]), liraglutide 1.8mg (MD=-1.23%, 95%Cl [-1.66, -0.80]) more effective than placebo. In terms of safety, the total incidence of adverse events was semaglutide 2.4mg > liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 1.0mg compare to placebo, the incidence of serious adverse events was liraglutide 3.0mg > liraglutide 1.8mg > semaglutide 2.4mg > semaglutide 1.0mg, the incidence of hypoglycemic events was semaglutide 2.4mg > liraglutide 3.0mg > semaglutide 1.0mg > liraglutide 1.8mg.
This meta-analysis indicates that all GLP-1RAs were more efficacious than placebo in people with obesity or overweight on efficacy. Semaglutide 2.4mg has an absolute advantage in weight loss and decreased HbA1c, but the incidence of total adverse events is also the highest and can cause hypoglycemia. In addition, although liraglutide 3.0mg was less effective than semaglutide 2.4mg, serious adverse events were still the most elevated.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>36510488</pmid><doi>10.2147/CLEP.S391819</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-8326-3214</orcidid><orcidid>https://orcid.org/0000-0002-1609-4377</orcidid><orcidid>https://orcid.org/0000-0003-1131-6417</orcidid><orcidid>https://orcid.org/0000-0003-3514-9086</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1179-1349 |
| ispartof | Clinical epidemiology, 2022-01, Vol.14, p.1463-1476 |
| issn | 1179-1349 1179-1349 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_24d9f5c996444915b47900676c50fa9c |
| source | Taylor & Francis; Publicly Available Content (ProQuest); PubMed Central |
| subjects | Analysis Bias Body mass index Clinical medicine Complications and side effects Coronaviruses COVID-19 Database searching Diabetes Drug dosages Epidemiology Evidence-based medicine Glucagon glucagon-like peptide-1 receptor agonists Hypoglycemia Internet/Web search services Intervention Liraglutide Medical research Medicine, Experimental Obesity Online searching Overweight Peptides Review semaglutide Sitagliptin Software reviews Systematic review Type 2 diabetes Weight control Weight loss |
| title | Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A04%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20Liraglutide%20and%20Semaglutide%20on%20Weight%20Loss%20in%20People%20with%20Obesity%20or%20Overweight:%20A%20Systematic%20Review&rft.jtitle=Clinical%20epidemiology&rft.au=Xie,%20Zeyu&rft.date=2022-01-01&rft.volume=14&rft.spage=1463&rft.epage=1476&rft.pages=1463-1476&rft.issn=1179-1349&rft.eissn=1179-1349&rft_id=info:doi/10.2147/CLEP.S391819&rft_dat=%3Cgale_doaj_%3EA733406516%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c619t-f73176c4384a9bde746e9ad24ec68437cd9431447ffd8d83e1e713fae428a68e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2755195220&rft_id=info:pmid/36510488&rft_galeid=A733406516&rfr_iscdi=true |